Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

Publisher： Karger

E-ISSN： 1423-0399|92|2|180-185

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.92, Iss.2, 2013-11, pp. : 180-185

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy

By  

Oncology Research and Treatment, Vol. 35, Iss. 10, 2012-09 ,pp. : 576-580

Karger

Access to resources Recommend Favorite

Gemcitabine plus Paclitaxel as First-Line Chemotherapy for Patients with Advanced Breast Cancer

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 18-23

Karger

Access to resources Recommend Favorite

Second-Line Chemotherapy of Advanced Disseminated Gastric Cancer after Cisplatin, Infusional 5-Fluorouracil, Folinic Acid (PLF): Benefit Dependant on Progression-Free Interval after First-Line Therapy

By  

Oncology Research and Treatment, Vol. 28, Iss. 10, 2005-09 ,pp. : 499-502

Karger

Access to resources Recommend Favorite

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

By  

Oncology, Vol. 67, Iss. 5-6, 2005-02 ,pp. : 376-381

Karger

Access to resources Recommend Favorite

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

By  

Oncology, Vol. 80, Iss. 3-4, 2011-06 ,pp. : 175-180

Karger

Access to resources Recommend Favorite